Zoetis (ZTS) : Traders are bullish on Zoetis (ZTS) as it has outperformed the S&P 500 by a wide margin of 4.14% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.11%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.08% in the last 1 week, and is up 4.54% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Zoetis Inc. is up 11.88% in the last 3-month period. Year-to-Date the stock performance stands at 10.34%. The stock has recorded a 20-day Moving Average of 2.92% and the 50-Day Moving Average is 6.93%.
Zoetis (NYSE:ZTS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $52.06 and $52.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $52.61. The buying momentum continued till the end and the stock did not give up its gains. It closed at $52.54, notching a gain of 0.48% for the day. The total traded volume was 2,714,250 . The stock had closed at $52.29 on the previous day.
Also, Barclays maintains its view on Zoetis (NYSE:ZTS) according to the research report released by the firm to its investors. The shares have now been rated Equal-weight by the stock experts at the ratings house. Barclays raises the price target from $45 per share to $49 per share on Zoetis . The rating by the firm was issued on August 4, 2016.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.